243 related articles for article (PubMed ID: 17504798)
21. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
[TBL] [Abstract][Full Text] [Related]
22. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
[TBL] [Abstract][Full Text] [Related]
24. [A randomized, double-blind, placebo-control study of once-daily inhaled tiotropium in chronic obstructive pulmonary disease].
Yin KS; Zhang DP; Shi Y; Sun LH; Min R; Xiao YL; Xia XR; Tan Y; Fu WZ
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jul; 33(7):519-23. PubMed ID: 20979799
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Baker WL; Baker EL; Coleman CI
Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
[TBL] [Abstract][Full Text] [Related]
26. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
[TBL] [Abstract][Full Text] [Related]
28. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
[TBL] [Abstract][Full Text] [Related]
29. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease.
Verkindre C; Bart F; Aguilaniu B; Fortin F; Guérin JC; Le Merre C; Iacono P; Huchon G
Respiration; 2006; 73(4):420-7. PubMed ID: 16484769
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
Zheng JP; Kang J; Cai BQ; Zhou X; Cao ZL; Bai CX; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
[TBL] [Abstract][Full Text] [Related]
31. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
[TBL] [Abstract][Full Text] [Related]
32. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
33. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
34. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.
Liesker JJ; Bathoorn E; Postma DS; Vonk JM; Timens W; Kerstjens HA
Respir Med; 2011 Dec; 105(12):1853-60. PubMed ID: 21802933
[TBL] [Abstract][Full Text] [Related]
35. [Tiotropium: a new therapeutic option in chronic obstructive pulmonary disease].
Corhay JL; Louis R
Rev Med Suisse; 2005 Aug; 1(30):1967-9, 1971-2. PubMed ID: 16200941
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of tiotropium in the prevention of exacerbations of COPD.
Anzueto A; Miravitlles M
Ther Adv Respir Dis; 2009 Jun; 3(3):103-11. PubMed ID: 19617284
[TBL] [Abstract][Full Text] [Related]
37. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
[TBL] [Abstract][Full Text] [Related]
38. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
39. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease.
Covelli H; Bhattacharya S; Cassino C; Conoscenti C; Kesten S
Pharmacotherapy; 2005 Dec; 25(12):1708-18. PubMed ID: 16305289
[TBL] [Abstract][Full Text] [Related]
40. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]